: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage.
TRG-035 is a monoclonal antibody designed to stimulate the growth of a "third set" of teeth in humans who have lost them due to decay, injury, or congenital conditions. NEWM-035
: The drug targets a specific protein called USAG-1 (uterine sensitization-associated gene-1). In nature, USAG-1 acts as a "biological parking brake" that prevents dormant tooth buds in the human jaw from developing into full teeth after the adult set has grown. : Launched in September 2024 at Kyoto University Hospital
The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi. : The drug targets a specific protein called
The code appears to be a misnomer or a very specific internal project identifier for which there is no broad public record. However, it is most frequently associated in recent medical research contexts with TRG-035 , a groundbreaking tooth regeneration drug currently undergoing human clinical trials in Japan.
: Preclinical trials on mice and ferrets—chosen for their similar dental structures—successfully produced new teeth with normal enamel and root structures and no significant side effects.